Actively Recruiting
Evaluating Safety and Effectiveness of OPN-375 Nasal Spray Twice Daily in Adolescents with Chronic Rhinosinusitis Without Nasal Polyps
Led by Optinose US Inc. · Updated on 2026-09-18
84
Participants Needed
24
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying adolescents aged 12 to 17 with chronic rhinosinusitis without nasal polyps to evaluate the effectiveness and safety of OPN-375, a nasal spray containing fluticasone propionate. This Phase 3 randomized, double-blind, placebo-controlled study involves about 84 adolescents who will be randomly assigned to receive either OPN-375 or a placebo over 12 weeks. The primary goal is to measure symptom changes from baseline using a composite nasal symptom score after 4 weeks of treatment. Participants will administer 186 micrograms of OPN-375 or a matching placebo intranasally twice daily for 12 weeks. The study includes a pharmacokinetic substudy with up to 14 participants to assess drug absorption. The trial is conducted with multiple visits screening, randomization, and end of study at Week 12, along with telephone check-ins at weeks 4 and 8 to monitor progress. Throughout the study, participants will complete daily symptom diaries and undergo assessments of nasal symptoms, quality of life, and acute exacerbations over 12 weeks. Key measurements include changes in nasal congestion, facial pain, nasal discharge, and patient-reported global impressions of change. Safety and adherence to medication use are monitored, with the total participation lasting about 15 weeks including screening and treatment periods.
CONDITIONS
Brief Title
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
Research Team
A
Alissa Sirbu
A
Amy Manley
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here